Actemra
Actemra
Actemra (tocilizumab) is a biologic medicine that helps reduce inflammation by blocking the interleukin-6 (IL-6) receptor. It’s used to treat conditions such as rheumatoid arthritis, giant cell arteritis, and certain forms of juvenile arthritis.
Delivery
5-7 day
In Stock
Yes
Guaranteed
Source Canadian/UK PharmaciesACTEMRA (generic name: tocilizumab) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, a key driver of inflammation in several autoimmune and inflammatory diseases. By inhibiting IL-6 signaling, ACTEMRA helps reduce inflammation, prevent joint damage, and improve physical function.
It is FDA-approved for multiple indications including:
-
Adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
-
Giant cell arteritis (GCA) in adults.
-
Systemic juvenile idiopathic arthritis (SJIA) and polyarticular juvenile idiopathic arthritis (PJIA) in children aged 2 years and older.
-
Severe or life-threatening cytokine release syndrome (CRS) caused by CAR-T cell therapy.
-
It was also granted emergency use authorization (EUA) during COVID-19 to treat hospitalized adults and pediatric patients with COVID-19 who required oxygen or mechanical ventilation.
ACTEMRA is administered either as an intravenous (IV) infusion or a subcutaneous (SC) injection, depending on the condition being treated. Common side effects include upper respiratory tract infections, headache, hypertension, and increased liver enzymes. Because it suppresses the immune system, it can increase the risk of serious infections.